

Notice Concerning Revision of the Full-Year Financial Guidance for Fiscal Year Ending March 31, 2024 (FY2023)

TOKYO, JAPAN – February 7, 2024 – Terumo Corporation (TSE: 4543) today announced that it revised the full-year financial guidance for the year ending March 31, 2024 (FY2023) which was announced on May 15, 2023.

1. Revised Full-Year Financial Guidance for FY2023 (From April 1, 2023 to March 31, 2024)

	Revenue (Million yen)	Adjusted operating profit (Million yen)	Operating profit (Million yen)	Profit for the year attributable to owners of the parent (Million yen)	Basic earnings per share (Yen)
Previous guidance (A)	854,000	151,000	132,500	101,000	135.98
Revised guidance (B)	906,000	157,500	140,000	105,000	141.18
Difference (B)-(A)	52,000	6,500	7,500	4,000	—
Rate of change	6.1%	4.3%	5.7%	4.0%	—
(Reference) Results for FY2022	820,209	138,025	117,332	89,325	119.00

2. Reasons of the Revision

Terumo anticipates consolidated revenue of 906 billion yen, an increase of 52 billion yen from the previous guidance. This increase is mainly due to the greater depreciation of the yen than originally anticipated at the beginning of this fiscal year.

Operating profit, adjusted operating profit and profit for the year attributable to owners of the parent are also anticipated to be an increase from the previous guidance.

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care,

and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Disclaimer

Among the information that Terumo discloses, the forward-looking statements including financial projections contain potential risks and uncertainty since these are made by Terumo based on limited information available at the moment of disclosure. Accordingly, it should be noted that actual results might differ from those statements due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.